RN486

a selective Bruton's tyrosine kinase inhibitor

Also Known As:

6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-(1-methyl-5-(5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl)-2H-isoquinolin-1-one

Networked: 4 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - RN486: 4

Experts

1.	Hill, Ronald J: 2 articles (01/2015 - 04/2012)
2.	Lou, Yan: 2 articles (01/2015 - 04/2012)
3.	Owens, Timothy D: 2 articles (01/2015 - 04/2012)
4.	DeMartino, Julie: 2 articles (09/2013 - 04/2012)
5.	Kim, Yong: 2 articles (09/2013 - 04/2012)
6.	Narula, Satwant: 2 articles (09/2013 - 04/2012)
7.	Postelnek, Jennifer: 2 articles (09/2013 - 04/2012)
8.	Woods, John: 2 articles (09/2013 - 04/2012)
9.	Xu, Daigen: 2 articles (09/2013 - 04/2012)
10.	Chen, Zhe-Sheng: 1 article (01/2020)

Related Diseases

1.	Arthritis (Polyarthritis) 04/01/2012 - "More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models. " 09/01/2013 - "We recently described a selective BTK inhibitor, RN486, that blocks B cell receptor (BCR) and Fcγ receptor signaling and is efficacious in animal models of arthritis. " 04/01/2012 - "In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis. " 04/01/2012 - "RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents."
2.	Carcinoma (Carcinomatosis) 01/01/2020 - "We found that RN486 significantly increased the efficacy of paclitaxel and doxorubicin in both drug-selected carcinoma cells and transfected cells overexpressing ABCB1. "
3.	Neoplasms (Cancer) 01/01/2020 - "In this study, we explored whether RN486, another BTK inhibitor, was competent to surmount ABCB1-mediated MDR and promote relevant cancer chemotherapy. " 01/01/2020 - "Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells."
4.	Hypersensitivity (Allergy) 04/01/2012 - "In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis. " 04/01/2012 - "RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents."
5.	Disease Progression 09/01/2013 - "The administration of RN486 completely stopped disease progression, as determined by histologic and functional analyses of glomerular nephritis. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Doxorubicin (Adriamycin)
3.	Agammaglobulinaemia Tyrosine Kinase
4.	Methotrexate (Mexate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)